Evidence map›Paper›PMID 31115870›Full record

ArticleJournal of neuro-oncology2019

Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells.

Parvez Vora, Mathieu Seyfrid, Chitra Venugopal, Maleeha A Qazi, Sabra Salim, Ruth Isserlin, Minomi Subapanditha, Erin O'Farrell, Sujeivan Mahendram, Mohini Singh and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 27 citations in OpenAlex.

  1. Targeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Integrins in cancer stem cells.Frontiers in cell and developmental biology · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Parvez VoraStem Cell and Cancer Research Institute, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Mathieu SeyfridStem Cell and Cancer Research Institute, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Chitra VenugopalStem Cell and Cancer Research Institute, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Maleeha A QaziStem Cell and Cancer Research Institute, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Sabra SalimDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada.
Ruth IsserlinDonnelly Centre and Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Minomi SubapandithaStem Cell and Cancer Research Institute, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Erin O'FarrellStem Cell and Cancer Research Institute, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Sujeivan MahendramStem Cell and Cancer Research Institute, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Mohini SinghDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada.
David BakhshinyanStem Cell and Cancer Research Institute, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Chirayu ChokshiStem Cell and Cancer Research Institute, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Nicole McFarlaneStem Cell and Cancer Research Institute, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Anna Dvorkin-GhevaDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
Kevin R BrownDonnelly Centre and Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Naresh MurtyDepartment of Surgery, McMaster University, Hamilton, ON, Canada.
Jason MoffatDonnelly Centre and Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Gary D BaderDonnelly Centre and Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Sheila K SinghStem Cell and Cancer Research Institute, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada. ssingh@mcmaster.ca.ORCID http://orcid.org/0000-0002-2076-8901
McMaster University · CAUniversity of Toronto · CA

Funding

Terry Fox Research Institute 1010
6 · The paper itself

Abstract

purposeGlioblastoma (GBM) is the most aggressive adult brain cancer, with a 15 month median survivorship attributed to the existence of treatment-refractory brain tumor initiating cells (BTICs). In order to better understand the mechanisms regulating the tumorigenic properties of this population, we studied the role of the polycomb group member BMI1 in our patient-derived GBM BTICs and its relationship with CD133, a well-established marker of BTICs.

methodsUsing gain and loss-of-function studies for Bmi1 in neural stem cells (NSCs) and patient-derived GBM BTICs respectively, we assessed in vitro self-renewal and in vivo tumor formation in these two cell populations. We further explored the BMI1 transcriptional regulatory network through RNA sequencing of different GBM BTIC populations that were knocked down for Bmi1.

resultsThere is a differential role of BMI1 in CD133-positive cells, notably involving cell metabolism. In addition, we identified pivotal targets downstream of BMI1 in CD133+ cells such as integrin alpha 2 (ITGA2), that may contribute to regulating GBM stem cell properties.

conclusionsOur work sheds light on the association of three genes with CD133-BMI1 circuitry, their importance as downstream effectors of the BMI1 signalling pathway, and their potential as future targets for tackling GBM treatment-resistant cell populations.

Indexed as

Gene Expression Regulation, NeoplasticGene Regulatory NetworksAC133 AntigenAnimalsApoptosisBrain NeoplasmsCell ProliferationGlioblastomaHumansMiceMice, Inbred NODMice, SCIDNeoplastic Stem CellsPolycomb Repressive Complex 1Tumor Cells, CulturedXenograft Model Antitumor AssaysAC133 AntigenBMI1 protein, humanPolycomb Repressive Complex 1PROM1 protein, humanBMI1CD133GlioblastomaPatient-derived brain tumor initiating cells

Identifiers

PMID31115870
OpenAlexW2944992875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.